Pfizer's quarterly earnings handily beat expectations, a boost for the company as it faces pressure from an activist investor ...
By Michael Erman and Bhanvi Satija (Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard ...
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...
Pfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.
Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the ...
Analyst Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.
Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk quarterly results, what's in the pipeline, ...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback